At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Axitinibdrug
Likely dose
Axitinib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Axitinib for Kidney Cancer. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if axitinib can help to control kidney cancer. The safety of this drug will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartFeb 2011
Primary CompletionFeb 2021
Study CompletionJun 2023
TodayJul 2026
First PostedDec 21, 2010
Enrollment StartFeb 1, 2011
Primary CompletionFeb 1, 2021
Study CompletionJun 5, 2023
TodayJul 2, 2026
Enrollment to primary: 10 yearsPosted 15.5 years ago
Interventions
Axitinibdrug
Starting dose: 5 mg by mouth twice each day for 12 weeks.